Robert Z. Orlowski, MD, PhD

Articles

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

September 18th 2024

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

September 11th 2024

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

September 11th 2024

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

Clinical Insights on the Patient Presentation & Treatment Course

September 4th 2024

The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status.

Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

September 4th 2024

The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.

Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

August 28th 2024

The panel evaluates selinexor's current role in the treatment landscape for multiple myeloma and explores its potential future applications and evolving significance in therapeutic strategies.

Overview of CAR T-cell Therapy Options in R/R MM

August 28th 2024

The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.

Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

August 21st 2024

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

August 21st 2024

The key opinion leaders examine selinexor combinations and dosing strategies they currently employ, while also addressing how the frequency of treatment-related adverse events (TRAEs) associated with selinexor varies with lower dosing regimens in the context of managing early relapse multiple myeloma.

Clinical Insights on Next Treatment Approach Steps

August 14th 2024

A panel of experts in relapsed/refractory multiple myeloma analyzes a patient case, detailing their clinical approach to optimize outcomes for a 68-year-old male presenting with early relapse multiple myeloma.

Clinical Scenario I: 68-yr Old Man with Early Relapse MM

August 14th 2024

Key opinion leaders present a clinical patient scenario involving a 68-year-old male patient presenting with early relapse multiple myeloma.

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

July 11th 2024

Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

June 25th 2024

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.

Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple Myeloma

December 7th 2015

Robert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.